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Abstract
Despite the critical role of Epidermal Growth Factor Receptor (EGFR) in glioblastoma pathogenesis [1,2], EGFR targeted
therapies have achieved limited clinical efficacy [3]. Here we propose an alternate therapeutic strategy based on the
conceptual framework of non-oncogene addiction [4,5]. A directed RNAi screen revealed that glioblastoma cells over-
expressing EGFRvIII [6], an oncogenic variant of EGFR, become hyper-dependent on a variety of DNA repair genes. Among
these, there was an enrichment of Base Excision Repair (BER) genes required for the repair of Reactive Oxygen Species (ROS)-
induced DNA damage, including poly-ADP ribose polymerase 1 (PARP1). Subsequent studies revealed that EGFRvIII over-
expression in glioblastoma cells caused increased levels of ROS, DNA strand break accumulation, and genome instability. In a
panel of primary glioblastoma lines, sensitivity to PARP1 inhibition correlated with the levels of EGFR activation and oxidative
stress. Gene expression analysis indicated that reduced expression of BER genes in glioblastomas with high EGFR expression
correlated with improved patient survival. These observations suggest that oxidative stress secondary to EGFR hyper-
activation necessitates increased cellular reliance on PARP1 mediated BER, and offer critical insights into clinical trial design.
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Introduction
Historically, cancer therapeutic development has largely been
driven by the principle of ‘‘oncogene addiction’’ – that cancer cells
require increased activity of selected oncogenes and therefore
tumor ablation can be achieved by inhibition of these oncogenes
[7]. While ‘‘oncogene addiction’’-based therapeutics have
achieved notable successes in some cancers [7], their application
to glioblastoma has yielded little efficacy. For instance, while
EGFR mutations or copy number alterations are found in nearly
50% of all glioblastomas [1,2], EGFR inhibition has yet to yield
significant improvements in clinical outcome [3]. The ineffective-
ness of such targeted therapy is explained in part by mutations in
downstream signaling molecules [3] and redundant signaling from
multiple co-activated receptor tyrosine kinases [8]. In this context,
it is evident that meaningful therapy will require co-extinction of
multiple oncogenes.
Emerging literature suggests an alternative strategy to the multi-
target approach [4,5]. These studies reveal that oncogene
activation introduces secondary physiologic changes that stress
cellular capacity for survival. Consequently, tumor cells become
hyper-dependent on processes required to compensate for these
stressful conditions. This phenomenon is termed ‘‘non-oncogene
addiction’’ since the compensatory processes required for tumor
survival are not oncogenic. As an example, RAS hyper-activation
in colon cancer cells results in increased mitotic aberrancy and
hyper-dependence on mitotic checkpoint function [5].
In this study, we explore the framework of ‘‘non-oncogene
addiction’’ as it relates to oncogenic EGFR activation. As hyper-
activation of several EGFR downstream effectors, including RAS
and STAT3, elicits increased DNA damage accumulation
[9,10,11], we tested whether the expression of a clinically pertinent
EGFR oncogene, EGFRvIII [6], caused increased requirement for
DNA repair as a form of non-oncogene addiction.
Results and Discussion
EGFRvIII over-expressing U87MG cells exhibited
increased reliance on BER genes
Given the mutually compensatory nature of many DNA repair
pathways [12,13], we reasoned that hyper-dependency on any
particular DNA repair process would be most evident when
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DNA damage. We selected Ionizing Radiation (IR) as a means of
introducing DNA damage since IR is universally utilized in
glioblastoma treatment. We adopted a siRNA screen-based
approach, reasoning that silencing of genes required for the
compensatory process might lead to preferential sensitization of a
glioblastoma line over-expressing EGFRvIII (U87MG-EGFRvIII)
relative to the parental line without such overexpression (U87MG).
We screened a targeted siRNA library including 480 siRNAs
directed against 240 DNA repair/damage response genes (Qiagen
DNA repair subset v2.0). The top 30 candidates from this screen
are shown in Fig. 1A.
Among the top candidate genes, we noted an enrichment of
Base Excision Repair (BER) genes required for the repair of
Reactive Oxygen Species (ROS) induced DNA damage (Fig. 1A)
[14]. Thymine DNA glycosylase (TDG) removes thymine glycol,
an oxidized thymine derivative [15]. Oxoguanine glycosylase 1
(OGG1) encodes the primary enzyme responsible for excision of 8-
oxoguanine, the most common type of ROS induced DNA
damage [16]. Poly-ADP ribose polymerase 1 (PARP1) catalyzes
the covalent transfer of ADP-ribose moieties to a variety of nuclear
proteins to initiate BER of oxidized nucleotides [17].
PARP1 inhibition recently emerged as a promising cancer
therapy [18,19,20]. PARP1 inhibition exerts preferential cytotox-
icity toward BRCA1/2 deficient tumors with defective homolo-
gous recombination (HR). Inactivation of BER by PARP1
inhibition leads to accumulation of DNA strand breaks that are
toxic without repair by HR. Our results suggest that PARP1
inhibition additionally affords targeting of glioblastomas with
hyperactive EGFR by disabling a mechanism required to
counteract the deleterious effects of ROS. To test this hypothesis,
we took the two independent siRNAs from the Qiagen library that
are directed against PARP1 and confirmed their EGFRvIII
specific radiosensitizing effects (Fig. S1). To further exclude the
possibility of ‘‘off-target’’ effects associated with RNAi, we
recapitulated this result using a siRNA distinct from the Qiagen
library siRNA (Fig. 1B) and two pharmacologic PARP1 inhibitors,
3-aminobenzamide (3-AB) and NU1025 (Fig. 1C). Without
radiation, PARP1 silencing or inhibition appeared to exert a mild
toxic effect against U87MG-EGFRvIII cells that was not seen with
U87MG cells. This effect was more pronounced for NU1025 in
comparison to 3-AB. Since this effect was also observed using a
PARP1 siRNA (Fig. 1B), the results suggest EGFR hyperactivation
generates a cell state with increased dependency on PARP1
related function, in the absence of exogenous DNA damage. This
dependency was magnified when combined with radiation. When
combined with 2 Gy IR, the siRNA caused an approximately
three-fold decrease in the clonogenic survival of the U87MG-
EGFRvIII cells relative to the parental U87MG cells (p,0.05 by
Student’s t-test). Similar effects were seen using NU1025 and 3-AB
though the magnitude of the effect (approximately two-fold) was
slightly less than that seen with the siRNA. Though these effects
were modest, they were consistently observed and statistically
significant (p,0.05 by Student’s t-test) (Fig. 1B, C). These results
were reproduced using the U373MG glioblastoma line containing
a tet-repressible EGFRvIII construct (Fig. 1D).
EGFRvIII over-expressing glioblastoma cells exhibited
increased levels of ROS, DNA damage, and genomic
instability
The increased reliance on BER in EGFRvIII over-expressing
cells suggests elevated ROS levels in these cells. To test this
hypothesis, U87MG and U87MG-EGFRvIII lines were assayed by
the ROS-sensitive fluorophore DCF-DA[10]. U87MG-EGFRvIII
cells exhibited markedly increased DCF-DA fluorescence, suggest-
ing elevated ROS accumulation (Fig. 2A). To exclude DCF-DA
dye related artifacts, the results were reproduced using two other
assays for ROS including 8-oxoguanine and dihydroethidium
fluorescence (Fig. S2). The increased DCF-DA fluorescence in the
U87MG-EGFRvIII cell line was abolished by treatment with the
EGFR inhibitor Erlotinib or EGFR siRNA (Fig. S3).
Unrepaired ROS induced DNA damages are often converted to
DNA double-strand breaks (DSBs) [21]. We thus determined
whether the increased ROS in U87MG-EGFRvIII cells culminate
in DSB accumulation [12]. We found increased levels of c-H2AX
and phospho-Chk2, two biomarkers for DSB accumulation [22],
in the U87MG-EGFRvIII line relative to the parental U87MG
cells (Fig. 2B). A 2–3 fold increase in the levels of c-H2AX and p-
CHK2 were also seen in xenograft tumors derived from U87MG-
EGFRvIII cells relative to those derived from U87MG, confirming
our results in vivo. We further confirmed our observation by c-
H2AX immunohistochemical staining of tumors derived from
U87MG-EGFRvIII and U87MG-EGFRKD (EGFRvIII-Kinase
Dead) cells. The U87MG-EGFRKD cells express a mutant
derivative of U87MG-EGFRvIII where the kinase activity was
inactivated by a point mutation in the ATP-binding site [23].
Consistently, the U87MG-EGFRvIII tumors harbored increased
number of cells with nuclear c-H2AX staining relative to the
U87MG-EGFRKD tumors (Fig. 2C) [24]. To ensure that these
observations were not unique to the U87MG cells, we recapitu-
lated these results using an U373MG line harboring a tet-
repressible EGFRvIII construct (Fig. S4).
DNA damage and strand breaks induced by excessive ROS
accumulation are harbingers of genomic instability [21,25]. Thus,
we sought to determine whether EGFRvIII induced ROS
predisposes accumulation of chromosomal aberrations. Sorted
diploid U87MG and U87MG-EGFRvIII were serially passaged.
The U87MG cells remained diploid after nine passages. However,
the U87MG-EGFRvIII cells exhibited progressive ploidy changes
(see increased .4N staining cells, Fig. 2D). Together, our results
suggest that EGFR hyper-activation causes increased ROS
accumulation, with resultant genomic instability.
EGFR over-expression correlated with ROS accumulation
and sensitivity to PARP1 inhibition
We wished to confirm our findings in clinical specimens by
assessing whether high 8-hydroxyguanosine (8-OG) IHC staining, a
well known marker for ROS levels [26], correlates with EGFR
immunostaining. Using a commercially available glioblastoma
microarray (US Biomax, Rockville, MD), we showed that EGFR
staining tends to parallel 8-OG staining (i.e. high EGFR staining
Figure 1. PARP1 inhibition preferentially radiosensitizes EGFRvIII hyperactive glioblastoma cells. (A) The top 30 siRNA targets that
preferentially sensitized U87MG-EGFRvIII cells relative to parental U87MG cells. (B) PARP1 silencing preferentially radiosensitized EGFRvIII expressing
U87MG, as measured by clonogenic survival (left and top right). PARP1 silencing efficiency (bottom right). (C) PARP1 inhibitors 3-AB and NU1025
radiosensitized EGFRvIII expressing U87MG. (D) PARP1 inhibitors NU1025 and 4-ANI preferentially radiosensitized U373MG cells expressing
EGFRvIII. The U373MG cells harbor a tet-repressible EGFRvIII construct. EGFRvIII + denotes U373MG tet-EGFRvIII grown in the absence of doxycycline.
EGFRvIII 2 denotes the cells grown in the presence of doxycycline. EGFRvIII expression levels were verified by Western blot (Fig. S3). Clonogenic
survival after PARP1 inhibitor treatment was expressed as a ratio to DMSO treated cells. p-values were calculated using Student’s t-test.
doi:10.1371/journal.pone.0010767.g001
EGFR, ROS and PARP1 Inhibition
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10767EGFR, ROS and PARP1 Inhibition
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10767glioblastomas tend to exhibit high 8-OG staining; Fig. 3A, p,0.05).
The same correlation was seen in low-grade gliomas (Fig. S5).
We further tested the correlation between EGFR hyperactivity,
ROS, and sensitivity to PARP1 using a panel of primary
glioblastoma cell lines. These lines were classified by DCF-DA
fluorescence intensity (Fig. 3A). The two lines with the highest
DCF-DA fluorescence exhibited the highest degree of EGFR
activation, as measured by levels of phospho-EGFR (Tyr 1173),
phospho-Stat3, and phospho-ERK1/2 [27] (Fig. 3B). Interesting-
ly, these lines were sensitive to PARP1 inhibition without IR. The
two lines with moderate DCF-DA fluorescence exhibited IR
sensitization upon PARP1 inhibition. Such sensitization was not
observed in the lines with low DCF-DA fluorescence (Fig. 3C).
RT-PCR of the EGFR transcript from the two high EGFR/DCF-
DA lines revealed that neither harbored the EGFRvIII variant
(Fig. S6). Together, these results suggest that EGFR hyper-
activation in the absence of EGFRvIII is sufficient to induce ROS
accumulation and sensitivity to PARP1 inhibition.
BER gene expression inversely correlated with survival in
patients afflicted with glioblastoma with high EGFR
expression
Since BER activity can be transcriptionally regulated [28], we
wished to determine whether EGFR hyperactive glioblastomas
increased transcription of BER genes in response to increased
oxidative stress. Using The Cancer Genome Atlas (TCGA)
glioblastoma database [1,29], tumors were stratified into groups
based on EGFR transcript level. Because most of the BER genes
functionally overlap [12,28], we developed a BER score (see
Methods) to assess global BER transcription as a proxy for overall
BER activity. The BER score did not appear to correlate with
EGFR transcript level (Fig. 4A). Given these findings, we reasoned
that tumors with high EGFR expression (high ROS) and low BER
gene expression (diminished compensatory mechanism) should
exhibit reduced survival fitness and therefore associate with
favorable patient survival. Indeed, patients with glioblastomas
exhibiting high EGFR expression and low BER score exhibited
improved survival (Fig. 4B). For the patient group with high EGFR
expressing glioblastomas, median survival times with low and high
BER scores were 14.5 and 9.2 months, respectively (log rank
p=0.01). Strikingly, such a survival benefit was not observed in the
low EGFR group (log rank p=0.99, Fig. 4C). Among the seven
TCGA patients with EGFRvIII expressing tumors, median survival
times with low and high BER scores were 22.6 and 8.9 months,
respectively (log rank p=0.008, Fig. 4D), further supporting the
importance of BER in EGFR hyperactive glioblastomas.
Our results indicate that ROS and DSB accumulation in EGFR
hyperactive glioblastoma cells is mitigated by BER and lay the
conceptual framework for the application of PARP1/BER
inhibition beyond the subset of tumors deficient in HR
[18,19,20]. To the extent that BER genes have yet been
implicated in glioblastoma oncogenesis, the framework constitutes
a form of ‘‘non-oncogene’’ addiction. This addiction occurs in the
absence of exogenous DNA damage. That is, the EGFR
hyperactive glioblastomas accumulated increased ROS/DSBs
and were hypersensitive to BER inhibition at baseline. IR induced
ROS/DSBs magnified this form of non-oncogene addiction by
‘‘overloading’’ the already taxed BER pathway. The efficacy of IR
in glioblastoma patients can, in part, be rationalized by this
paradigm. A corollary of this paradigm is that therapeutic insights
can be derived by mapping the intersection between the various
forms of non-oncogene addiction and the molecular effects of
existing glioblastoma therapies.
The work further provides several insights into the clinical
translation of the ‘‘non-oncogene addiction’’ framework. First and
foremost, the effects of therapies designed based on the principles
of ‘‘oncogene addiction’’ and of ‘‘non-oncogene addiction’’ are
inherently antagonistic. In our study, EGFR inhibition leads to
reduction of ROS, obviating the need for BER. In this context,
combination of PARP1 and EGFR inhibition would not be
desirable. Additionally, there appears to be sufficient variability in
the pathways of oncogenesis [30], such that not every EGFR
hyperactive glioblastoma develops increased BER capacity. The
discrepancy between oncogenic stress and stress support pathways
in select tumors offers an opportunity to maximize therapeutic
efficacy. We propose the use of the transcriptome-based BER
score and EGFR status as a means of capitalizing on this
opportunity in clinical trial design involving BER inhibitors.
Finally, our screen results suggest that a much larger set of non-
oncogenes serves to support EGFRvIII induced oncogenic stress.
Indeed, EGFR activation has been shown to modulate potential
oncogenic stress support pathways including DSB repair [31] and
apoptosis [32]. Understanding the physiologic interactions be-
tween the various stress support pathways should afford the
development of synergistic drug combinations [4] ultimately
required for meaningful therapeutic efficacy.
Materials and Methods
Cell culture and reagents
The U87MG, U87MG-EGFRvIII, U87MG-EGFRKD, and
U373MG tet-EGFRvIII cell lines were obtained from Dr. Webster
K. Cavenee and propagated as reported [6,23]. Primary glioblas-
toma cell lines were derived from fresh surgical specimens after
obtaining written informed consent under Institutional Review
Board-approved Dana-Farber/Harvard Cancer Center Protocol 07-
231. These were passaged as described for U87MG; passage 2–3
lines were used. NU1025 (Sigma Aldrich, St. Louis, MO), 3-
aminobenzamide (3-AB, Sigma), 4-amino-1,8-naphthalimide (4-
ANI, Calbiochem, Gibbstown, NJ) and doxycycline (Sigma) were
dissolved in DMSO. N-acetylcysteine (NAC, Sigma) and hydrogen
peroxide (H2O2, Sigma) were dissolved in culture media.
Reactive Oxygen Species (ROS) and chromosomal
instability assays
Levels of ROS in U87MG and U87MG-EGFRvIII cells were
assessed using the OxyDNA Assay Kit (Calbiochem), DCF-DA
(Invitrogen, Carlsbad, CA), and dihydroethidium (Invitrogen) accord-
ing to manufacturers’ instructions. To assay chromosomal instability,
Figure 2. EGFR hyperactivation increases oxidative stress and DNA damage accumulation in glioma cells. (A) EGFRvIII expression is
associated with increased DCF-DA fluorescence. A representative experiment (top). The mean and standard deviation of DCF-DA fluorescence derived
from three independent experiments (bottom). (B) EGFRvIII expression is associated with increased c-H2AX and p-Chk2 accumulation in tissue culture
(T.C.) and xenograft models. Intensities of c-H2AX and p-Chk2 bands were quantified and normalized to the intensity of the RAN loading control
(bottom). The experiment was repeated three times with consistent results. A representative experiment is shown. (C) IHC of mouse xenografts
confirmed that EGFRvIII expressing U87MG cells exhibit increased c-H2AX accumulation. Scale bar, 100 mm( 6400), 40 mm( 61,000). Percent of cells
with c-H2AX homogeneous (large arrow) or punctate nuclear staining (thin arrow, left panel) were quantified (right panel). (D) EGFRvIII expression in
U87MG is associated with progressive ploidy alterations.
doi:10.1371/journal.pone.0010767.g002
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passaged every 3 days, and cell cycle distributions were analyzed by
flow cytometry after propidium iodide staining [33].
siRNA library screen and validation
Cells were transfected with 20 nM of siRNA oligonucleotides
using HiPerfect transfection reagent (QIAGEN, Valencia, CA).
Figure 3. Clinical correlation between EGFR expression, oxidative stress and sensitivity to PARP inhibition. (A) EGFR expression
correlated with 8-hydroxyguanosine (8-OG) staining in a glioblastoma microarray. Glioblastomas were stratified into high or low EGFR staining
groups. Within each group, the percent of cases with high 8-OG staining is shown in white; low 8-OG staining in gray (right). Representative pictures
of high and low staining patterns of EGFR and 8-OG are shown (left). Scale bar, 200 mm (6200), 50 mm (6600). (B) Correlation between DCF-DA
fluorescence and EGFR. Primary glioblastoma lines were grouped based on DCF-DA staining (left). p-EGFR, p-Stat3, and p-ERK1/2 levels were assessed
(right). (C) the level of oxidative stress/EGFR activation correlated with sensitivity to PARP1 inhibition.
doi:10.1371/journal.pone.0010767.g003
EGFR, ROS and PARP1 Inhibition
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10767Twenty-four hours after transfection, cells were irradiated with
5 Gy IR. Viability was assessed 72 hours after irradiation using
the CellTiter-Glo Luminescent Cell Viability Assay kit (Pro-
mega, Madison, WI). The experiment was performed twice for
each cell line on independent days to allow for statistical analysis.
The corrected viability for cells transfected with each siRNA was
calculated as a percentage of the mean viability of the control
wells containing GFP or scrambled siRNAs (Qiagen DNA repair
subset v2.0) for each 96-well plate. The corrected viability of the
irradiated cells was then subtracted from the corrected viability
of the non-irradiated cells to calculate the relative viability after
irradiation for each respective gene target. The mean of these
values (referred to as the mean percent viability after irradiation)
was calculated (averaging the two distinct siRNAs directed
against the same target gene in each of the two experiments) and
termed the radiation effect. The radiation effect derived from the
U87MG-EGFRvIII line was then subtracted from that derived
from the U87MG line. This value was expressed as a percent of
the radiation effect for EGFRvIII and reported as the EGFRvIII
IR index. The siRNA targets are ranked based on this index
[33].
Immunoblotting and immunohistochemistry
Western blotting and IHC were performed using standard
techniques as previously described [6,33]; see Methods S1 for
details.
siRNA transfection
The initial siRNA screen was performed using the Qiagen
DNA repair subset v2.0 siRNA library. Subsequent PARP1
confirmation studies were performed using an independent
siRNA directed against PARP1 (ON-TARGET plus J-006656-
05-0005, Dharmacon, Denver CO). Qiagen Hs_EGFR_12 (59-
CAGGAACTGGATATTCTGAAA-39) was used for EGFR
silencing. The control siRNA was obtained from Qiagen (AllStars
Negative Control and anti-GFP: 59-AACACTTGTCACTA-
CTTTCTC-39). The siRNA transfections were done by using
either RNAiMax (Invitrogen) or HiPerfect reagent (Qiagen). In
brief, 1610
5 cells were plated on 6-well plates the day before
transfection, then 20 nM of siRNA was transfected according
to manufacturer’s protocol for 24 hours prior to subsequent
manipulations.
Viability assays
Cells were seeded into 10 cm plates and treated for 24 hours
with various siRNAs or PARP inhibitors, and then irradiated with
ionizing radiation (IR). Cells were trypsinized 24 hours after
irradiation and plated in serial dilution. 10–14 days after
irradiation, cells were fixed and stained with crystal violet (0.1%)
and numbers of colonies were counted. All experiments were
performed in triplicates and repeated at least twice. For
doxycycline experiments, cells were treated with doxycycline for
72 hours prior to subsequent manipulation.
Figure 4. Association between EGFR and BER gene expression and clinical outcome. (A) In clinical specimens, EGFR expression and BER
score showed no correlation. (B) Patients with high EGFR expressing glioblastomas with low BER score exhibited improved survival, log rank
p=0.01. Red: low BER score; blue: high BER score; median survival times of 14.5 and 9.2 months, respectively. (C) BER gene expression did not
impact patients with glioblastomas exhibiting low EGFR expression, log rank p=0.99. (D) Patients with EGFRvIII expressing glioblastomas with low
BER score exhibited improved survival, log rank p=0.008. Red: low BER score; blue: high BER score; median survival times of 22.6 and 8.9 months,
respectively.
doi:10.1371/journal.pone.0010767.g004
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Total RNA was isolated from primary glioblastoma cultures,
U87MG and U87MG-EGFRvIII cell lines (2610
6 cells) using the
RNeasy Mini kit (Qiagen, Valencia, CA). Standard RT-PCR was
done with primers designed to flank the deletion of exons 2 to 7
(59-ATGCGACCCTCCGGGACG-39 and 59-ATTCCGTTACA-
CACTTTGCGGC-39; final reaction concentration=100 nM).
Reverse transcription was done at 50uC for 30 minutes followed
by enzyme inactivation at 95uC for 15 minutes. This was followed
by 35 cycles of (94uC: 1 min; 55uC: 1 min; 72uC: 1 min) and a
final extension of 72uC for 10 minutes. PCR products were
visualized on a 1% agarose gel containing ethidium bromide.
Biostatistical analysis
Glioblastoma gene expression and correlating clinical data were
obtained from The Cancer Genome Atlas (http://www.
broadinstitute.org/,gadgetz/TCGA/TCGA_206_median.txt)
[1,29]. Tumors were categorized as showing high (greater than
mean) vs. low EGFR expression. An exhaustive literature search
revealed 24 genes implicated in BER (PARP1, PARP2, XRCC1,
LIG3, POLB, UNG, SMUG1, MBD4, TDG, DUT, OGG1,
NTHL1, NEIL1, NEIL2, NEIL3, NUDT1, MUTYH, APEX1,
APEX2, PNKP, MGMT, ALKBH2, ALKBH3 and MPG) [12].
For each tumor, one point was added for each BER gene showing
greater than mean expression. The sum of these points was termed
the BER score. A high BER score was defined as one greater than
12. Kaplan-Meier plots were generated using JMP (SAS Institute,
Cary, NC). Seven tumors were previously identified via SNP
array-based copy number analysis as expressing the EGFRvIII
mutation; these showed a loss of exons 2–7 relative to downstream
EGFR exons [1,29].
Supporting Information
Methods S1 Supplemental Materials and Methods.
Found at: doi:10.1371/journal.pone.0010767.s001 (0.05 MB
DOC)
Figure S1 PARP1 silencing preferentially radiosensitized EGFR-
vIII hyperactive glioblastoma cells. Two independent siRNAs against
PARP1 preferentially sensitized U87MG-EGFRvIII cells to IR (left).
The efficency of knock down is shown in the right column. The
siRNAs were taken from the Qiagen DNA repair subset v2.0. Cells
were transfected with 20 nM of siRNA oligonucleotides using
HiPerfect transfection reagent (QIAGEN, Valencia, CA). Twenty-
four hours after transfection, cells were irradiated with 2 Gy IR.
Viability was assessed by clonogenic survival as described in methods.
In parallel, cells were seeded into a 10 cm plate and treated as
described above. RNA extraction was performed at 72 hours after
irradiation. The Qiagen QuantiTect SYBR Green RT-PCT Kit was
used to quantify the efficiency of gene silencing as per manufacturer’s
instructions. Each experiment was repeated twice. Results from a
representative experiment is shown.
Found at: doi:10.1371/journal.pone.0010767.s002 (0.12 MB TIF)
Figure S2 EGFRvIII over-expression induced increased ROS
accumulation. (A) Levels of 8-oxoguanine, the most common
form of ROS induced DNA damage, are increased in U87MG-
EGFRvIII cells relative to U87MG cells. U87MG and U87MG-
EGFRvIII cells were harvested, washed with PBS, and fixed with
ice-cold 70% ethanol. The cells were then washed with PBS and
incubated with FITC-conjugated 8-oxoguanine probe (1:100) for
60 min. Fluorescence was measured by FACS. (B) EGFRvIII
over-expression in U87MG is associated with increased ROS
accumulation as gauged by dihydroethidium fluorescence.
U87MG and U87MG-EGFRvIII cells were harvested, washed
with PBS, and incubated with dihydroethidium (5 mM) for
15 min. As a positive control, U87MG cells were also treated
with 0.03% hydrogen peroxide (H2O2) for 30 min before
harvest. Levels of dihydroethidium fluorescence were measured
by FACS. Each bar depicts mean dihydroethidium fluorescence
intensity 6 SEM (normalized to unstained control) derived from
triplicates.
Found at: doi:10.1371/journal.pone.0010767.s003 (0.47 MB TIF)
Figure S3 EGFR inhibition or silencing decreased ROS level in
U87MG-EGFRvIII cells. (A) EGFR inhibition by erlotnib in
U87MG-EGFRvIII cells decreased ROS levels. U87MG-EGFR-
vIII cells were treated with DMSO or erlotinib (10 mM) or N-
acetylcysteine (NAC, Sigma) as a positive control for 48 hours.
Cells were harvested, washed with PBS, and incubated with DCF-
DA (5 mM) for 15 min. Cells were then washed with PBS and
analyzed by FACS. (B) EGFR silencing reduces ROS levels in
U87MG-EGFRvIII cells. U87MG-EGFRvIII cells were transfect-
ed with siRNA against EGFR or a control siRNA. Cells were
cultured for another 72 hours. DCF-DA fluorescence was
measured by FACS (left panel). Efficiency of EGFRvIII silencing
is shown in the right panel.
Found at: doi:10.1371/journal.pone.0010767.s004 (0.48 MB TIF)
Figure S4 EGFRvIII expression is associated with DNA damage
accumulation in U373MG cells. U373MG cells harboring a tet-
repressible EGFRvIII construct [1] were treated with doxycycline
(1 mM) or vehicle for 72 hours. Cell lysates were prepared and
levels of c-H2AX and p-Chk2 were analyzed (top panel). Intensity
of c-H2AX and p-Chk2 bands were quantified and normalized to
the intensity of the RAN loading control (bar graph in the bottom
panel).
Found at: doi:10.1371/journal.pone.0010767.s005 (0.38 MB
TIF)
Figure S5 EGFR expression correlates with 8-hydroxyguano-
sine (8-OG) staining in low-grade gliomas. A low-grade gliomas
microarray (US Biomax) was stained for EGFR and 8-OG (see
Supplemental Materials and Methods). Samples were stratified
into high or low EGFR staining groups. Within each group, the
percent of cases with high 8-OG staining is shown in white; low 8-
OG staining cases shown in gray. High EGFR staining
glioblastomas tend to exhibit high 8-OG staining (p,0.05 by
Student’s t-test).
Found at: doi:10.1371/journal.pone.0010767.s006 (0.18 MB TIF)
Figure S6 Primary glioblastoma lines used did not harbor
EGFRvIII transcript. EGFR transcripts in primary glioblastoma
lines were examined by RT-PCR. Ethidium bromide stained gel
showing EGFR PCR products from two primary glioblastoma
lines, GBM1 and GBM2. mRNAs isolated from U87MG
(expressing EGFR) and U87MG-EGFRvIII were used as
controls.
Found at: doi:10.1371/journal.pone.0010767.s007 (0.31 MB TIF)
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